Calidi Biotherapeutics Inc Ordinary Shares CLDI
News
Calidi Biotherapeutics Presented New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026, Including Highlighting the Potential of its RedTail Gene Medicine Platform to Turn Tumors into Localized TCE Biofactories
Calidi Biotherapeutics to Present New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026
Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency
Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering
Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
